Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

A Study of HIV-Disease Development in Aging

A Phase II Exploratory Study Examining Immunologic and Virologic Indices in Two Age-Differentiated Cohorts of HIV-Infected Subjects to Explore the Basis of Accelerated HIV-Disease Progression Associated With Aging

The purpose of this study is to better understand the relationship between age and HIV disease progression.

This study will explore the possible relationship between age and HIV disease progression. Older age is an important risk factor for faster disease development, but older people may respond better to combination drug therapy. This relationship needs to be understood better.

Studieoversikt

Detaljert beskrivelse

Older age is an important risk factor for accelerated HIV-disease progression. However, the virologic response to highly active antiretroviral therapy (HAART) may be superior in older persons. A better understanding of the immunologic, virologic, and behavioral mechanisms that underlie these age-related differences may help to elucidate critical immune responses that are necessary to control the progression of HIV-disease.

Patients are grouped according to age. Group A consists of patients between the ages of 13 and 30 years. Group B consists of patients age 45 years or older. All patients receive open-label lopinavir/ritonavir (LPV/RTV) plus emtricitabine (FTC) plus stavudine (d4T) for 96 [AS PER AMENDMENT 06/04/02: 192] weeks. Study visits occur at pre-entry, entry, and Weeks 4, 8, 12, 16, and 24 then every 12 weeks thereafter through Week 96 [AS PER AMENDMENT 06/04/02: Week 192]. Clinical assessments, safety laboratory tests, CD4 cell count monitoring, lymphocyte phenotyping, and HIV-1 RNA determinations are performed routinely. Blood samples are stored for further immunology and virology studies. Patients may volunteer to participate in virology substudy A5020s and either immunology substudy A5016s or A5017s [AS PER AMENDMENT 06/04/02: Substudy A5017s has been eliminated.]

Studietype

Intervensjonell

Registrering

90

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • California
      • Los Angeles, California, Forente stater, 900331079
        • USC CRS
      • Palo Alto, California, Forente stater, 943055107
        • Stanford CRS
      • San Francisco, California, Forente stater, 941102859
        • Ucsf Aids Crs
      • San Jose, California, Forente stater, 951282699
        • Santa Clara Valley Med. Ctr.
      • San Mateo, California, Forente stater, 943055107
        • San Mateo County AIDS Program
      • San Rafael, California, Forente stater, 94903
        • Marin County Dept. of Health & Human Services, HIV/AIDS Program & Specialty Clinic
    • Colorado
      • Aurora, Colorado, Forente stater, 80262
        • University of Colorado Hospital CRS
    • Florida
      • Miami, Florida, Forente stater, 331361013
        • Univ. of Miami AIDS CRS
    • Hawaii
      • Honolulu, Hawaii, Forente stater, 96816
        • Univ. of Hawaii at Manoa, Leahi Hosp.
      • Honolulu, Hawaii, Forente stater, 96816
        • Queens Med. Ctr.
    • Illinois
      • Chicago, Illinois, Forente stater, 60611
        • Northwestern University CRS
      • Chicago, Illinois, Forente stater, 60612
        • Rush Univ. Med. Ctr. ACTG CRS
    • Indiana
      • Indianapolis, Indiana, Forente stater, 46202
        • Methodist Hosp. of Indiana
      • Indianapolis, Indiana, Forente stater, 46202
        • Indiana Univ. School of Medicine, Wishard Memorial
      • Indianapolis, Indiana, Forente stater, 462025250
        • Indiana Univ. School of Medicine, Infectious Disease Research Clinic
    • Maryland
      • Baltimore, Maryland, Forente stater, 21287
        • Johns Hopkins Adult AIDS CRS
    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02114
        • Massachusetts General Hospital ACTG CRS
      • Boston, Massachusetts, Forente stater, 02118
        • Bmc Actg Crs
      • Boston, Massachusetts, Forente stater, 02215
        • Brigham and Women's Hosp. ACTG CRS
      • Boston, Massachusetts, Forente stater
        • Beth Israel Deaconess Med. Ctr., ACTG CRS
      • Fall River, Massachusetts, Forente stater
        • SSTAR, Family Healthcare Ctr.
    • Minnesota
      • Minneapolis, Minnesota, Forente stater, 55455
        • University of Minnesota, ACTU
    • Missouri
      • Saint Louis, Missouri, Forente stater
        • Washington U CRS
    • New York
      • New York, New York, Forente stater, 10003
        • Beth Israel Med. Ctr., ACTU
      • New York, New York, Forente stater, 10016
        • NY Univ. HIV/AIDS CRS
      • New York, New York, Forente stater, 10029
        • Mt. Sinai Med. Ctr. A0404 CRS
      • New York, New York, Forente stater
        • Columbia Univ., HIV Prevention and Treatment Medical Ctr.
      • New York, New York, Forente stater
        • Mt.Sinai Med. Ctr. A1009 CRS
      • Rochester, New York, Forente stater, 14642
        • Univ. of Rochester ACTG CRS
      • Rochester, New York, Forente stater, 14642
        • AIDS Care CRS
      • Rochester, New York, Forente stater, 14607
        • Trillium Health ACTG CRS
    • North Carolina
      • Chapel Hill, North Carolina, Forente stater, 275997215
        • Unc Aids Crs
      • Durham, North Carolina, Forente stater, 27710
        • Duke Univ. Med. Ctr. Adult CRS
    • Ohio
      • Cleveland, Ohio, Forente stater, 44106
        • Case CRS
      • Cleveland, Ohio, Forente stater, 441091998
        • MetroHealth CRS
      • Columbus, Ohio, Forente stater, 432101228
        • The Ohio State University Medical Center
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forente stater, 19104
        • Hosp. of the Univ. of Pennsylvania CRS
      • Philadelphia, Pennsylvania, Forente stater, 19104
        • Philadelphia Veterans Admin. Med. Ctr. A6205 CRS
    • Rhode Island
      • Providence, Rhode Island, Forente stater, 02906
        • The Miriam Hosp. ACTG CRS
      • Providence, Rhode Island, Forente stater
        • Rhode Island Hosp.
    • Tennessee
      • Nashville, Tennessee, Forente stater
        • Vanderbilt Therapeutics CRS
    • Texas
      • Dallas, Texas, Forente stater, 75235-9173
        • Univ. of Texas Southwestern Med. Ctr., Amelia Court Continuity Clinic
      • Galveston, Texas, Forente stater, 77555-0435
        • Univ. of Texas Medical Branch, ACTU
    • Washington
      • Seattle, Washington, Forente stater, 98104
        • University of Washington AIDS CRS
      • San Juan, Puerto Rico, 009365067
        • Puerto Rico-AIDS CRS

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

13 år og eldre (Barn, Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria

Patients may be eligible for this study if they:

  • Are HIV-positive.
  • Are between 13 and 30 years old (need consent of parent or guardian if under 18), or are more than 44 years of age.
  • Have a viral load of more than 2000 copies/ml within 60 days of study entry.
  • Have a CD4 cell count of less than 600 cells/mm3 within 60 days of study entry. (This reflects a change in the CD4 cell count requirement.)
  • Agree to use effective methods of birth control (such as condoms) during and for 12 weeks after the study.

Exclusion Criteria

Patients will not be eligible for this study if they:

  • Are pregnant or breast-feeding.
  • Have an AIDS-related cancer (except Kaposi's sarcoma) requiring chemotherapy.
  • Have hepatitis within 30 days of study entry.
  • Have diarrhea (more than 3 liquid stools/day for at least 14 days) within 30 days of study entry.
  • Are receiving chemotherapy or radiation treatment.
  • Have taken antiretroviral drugs for more than 14 days.
  • Have received an HIV vaccine within 30 days of study.
  • Have a serious illness or infection within 14 days of the study.
  • Have other serious conditions that might interfere with study participation.
  • Have taken or plan to take certain other drugs that might affect the study results.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studiestol: Robert Kalayjian

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart

1. oktober 2000

Studiet fullført (Faktiske)

1. april 2005

Datoer for studieregistrering

Først innsendt

7. august 2000

Først innsendt som oppfylte QC-kriteriene

30. august 2001

Først lagt ut (Anslag)

31. august 2001

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

1. november 2021

Siste oppdatering sendt inn som oppfylte QC-kriteriene

28. oktober 2021

Sist bekreftet

1. oktober 2021

Mer informasjon

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere